secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2026-08-19T11:01:13+00:00
Accession:  0001372514-26-000077
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora licenses South Korean rights for KIO-301 to CKD for $1M upfront plus milestones and royalties
--------------------------------------------------------------------------------

- $1M upfront payment from CKD for exclusive South Korean rights to KIO-301 for retinitis pigmentosa and other ophthalmic indications.
- Eligible for development, regulatory, and sales milestone payments plus double-digit royalties on net sales in South Korea.
- CKD to handle development and commercialization in South Korea; partners Théa, Senju, and CKD to coordinate single global Phase 3 trial.
- Kiora to focus on KIO-104 and ion channel modulators; evaluating strategic transactions to expand pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000077/0001372514-26-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000077/kprx-20260819.htm
  HTML page:      https://secwatch.observer/filing/0001372514-26-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer